Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

3.8K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.8K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

2.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Extreme Cardiovascular Risk and LDL-C Target Achievement in People With HIV.

Open forum infectious diseases·2026
Same author

Perinatal Health Promotion in Indigenous Maternal Health: A Scoping Review of Peer-Reviewed Evidence and Australian Community-Controlled Programs.

International journal of environmental research and public health·2026
Same author

Blood pressure control in people with HIV and established atherosclerotic cardiovascular disease: a real-world descriptive analysis.

AIDS (London, England)·2026
Same author

[Eugene Braunwald obituary].

Giornale italiano di cardiologia (2006)·2026
Same author

Challenges and Perspectives in Optimising the Treatment of Arterial Hypertension: Role of the Ramipril-Amlodipine-Hydrochlorothiazide Single-Pill Combination.

High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension·2026
Same author

Obstetric, sociodemographic, and clinical factors influencing C-section trends in Australia, from 2007 to 2017: An analysis of population-based perinatal data in Queensland using the Robson classification.

European journal of obstetrics, gynecology, and reproductive biology·2026

相关实验视频

Updated: May 2, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K

在心肌梗塞后,通过n-3多不和脂肪酸预防突然死亡的早期保护:对意大利人群对心肌梗塞生存研究 (GISSI) - 预防结果的时间分析.

Roberto Marchioli1, Federica Barzi, Elena Bomba

  • 1Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy. marchioli@negrisud.it

Circulation
|May 9, 2002
PubMed
概括

在心肌梗塞幸存者中,n-3多不和脂肪酸 (PUFA) 显著降低了总死亡率和突然心脏死亡. 早期观察到益处,支持抗心律失常效应和改善心血管结果.

更多相关视频

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.9K
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

1.0K

相关实验视频

Last Updated: May 2, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.9K
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

1.0K

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.
  • 营养科学 营养科学

背景情况:

  • 在GISSI-Prevenzione试验中,研究了心肌梗塞幸存者的n-3多不和脂肪酸 (PUFA).
  • 之前的研究表明,n-3PUFA对死亡率有好处.

研究的目的:

  • 评估n-3PUFA对最近心肌梗塞幸存者的死亡率的时间效应.
  • 评估各种心血管事件的早期疗效.

主要方法:

  • 11,323名心肌梗塞幸存者被随机分配给n-3PUFA,维生素E,两者,或安慰剂.
  • 治疗意图分析与数据审查长达12个月.
  • 通过依赖时间的生存分析评估早期疗效.

主要成果:

  • 在3个月后,n-3 PUFA 治疗显著降低了总死亡率 (RR 0.59).
  • 突然死亡风险显著降低了4个月 (RR 0.47).
  • 心血管,心脏和冠状动脉死亡在6-8个月后显著下降.

结论:

  • 低剂量n-3PUFA对总和突然死亡的早期好处支持一种抗失常效应.
  • 这些发现与现有的实验室和临床证据一致.
  • n-3 PUFA 为心肌梗塞后患者提供了有价值的治疗选择.